玛巴沙洛韦（Baloxavir marboxil）

CAS：1985606-14-1

Status：Pilot validation completed

Baloxavir marboxil, marketed as Xofluza, is an antiviral medication for the treatment of acute uncomplicated influenza. Developed by Shionogi & Co., Ltd. and later partnered with Roche, it is a first-in-class, single-dose oral drug. Its mechanism of action involves inhibiting the cap-dependent endonuclease (CEN), an enzyme essential for viral replication. This is different from neuraminidase inhibitors (e.g., oseltamivir). A key advantage is its rapid reduction of viral load, significantly shortening the duration of flu symptoms with just one dose. It is also active against some oseltamivir-resistant strains.

巴洛沙韦马布西酯（商品名：速福达）是一种用于治疗急性无并发症流感的抗病毒药物。由日本盐野义（Shionogi）原研，并与罗氏合作推广。它是全球首个具有全新作用机制的单剂量口服流感药。其作用机制是抑制帽状结构依赖性核酸内切酶（CEN），该酶对流感病毒复制至关重要，这与神经氨酸酶抑制剂（如奥司他韦）不同。其主要优势在于能快速降低病毒载量，仅需服用一次即可显著缩短流感症状持续时间，且对某些奥司他韦耐药株也有效。